Jobs
-
Spyryx Biosciences, which recently initiated a Phase 2 study of its SPX-101 inhaled SPLUNC1-derived peptide for the treatment of cystic fibrosis, announced that former United Therapeutics CEO Roger Jeffs has joined its board of directors.… Read more . . .
-
3P innovation, which recently launched a new robotic filling machine capable of filling inhalers as well as capsules, says that it has started work on a new facility at Tournament Fields near Warwick, UK. The… Read more . . .
-
Aradigm Corporation said that the FDA’s Antimicrobial Drugs Advisory Committee (ADAC) has voted against approval of the company’s NDA for Linhaliq dual release inhaled ciprofloxacin for the treatment of P. aeruginosa lung infections in non-cystic… Read more . . .
-
Eurocine Vaccines has received authorization from the Swedish Medical Products Agency for a Phase 1/2 clinical study of its intranasal quadrivalent influenza vaccine Immunose Flu during the current flu season, the company said. Eurocine Vaccines… Read more . . .
-
Boehringer Ingelheim announced that its Respimat soft mist inhaler has received an Ease of Use Commendation from the Arthritis Foundation. In order to receive the commendation, products submitted by manufacturers to the Arthritis Foundation for… Read more . . .
-
Functional respiratory imaging specialist FLUIDDA has announced a new research collaboration with a team at the University of California, San Francisco led by Professor John Fahy that will use FLUIDDA technology “to understand the effects… Read more . . .
-
3P Innovation has announced the launch of a new version of its R500 Robotic Capsule and Device Filler which is scalable and capable of filling inhalers directly as well as filling capsules. According to 3P,… Read more . . .
-
Deepro nebulizer maker HCmed has announced that Vivo Capital’s PANDA Fund has become a strategic investor as of December 27, 2017, saying, “As a healthcare focused investment firm, Vivo will fully support HCmed’s strategic plan… Read more . . .
-
Inhaled drug developer Savara has announced the appointment of Peter Ginsberg as VP of Business Development. Ginsberg was most recently VP of Business Development at BioDelivery Sciences International and had previously held business development positions… Read more . . .
-
A Phase 3 trial of Liquidia Technologies’ LIQ861 treprostinil DPI for the treatment of pulmonary arterial hypertension (PAH) is underway, the company said. The study is expected to enroll a minimum of 100 PAH patients… Read more . . .
Featured event:
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
July 13-July 16: 2026 ISAM Congress, Taipei, Taiwan
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK